StockNews.com Begins Coverage on Fresenius Medical Care (NYSE:FMS)

Equities researchers at StockNews.com began coverage on shares of Fresenius Medical Care (NYSE:FMS - Get Free Report) in a note issued to investors on Friday. The firm set a "strong-buy" rating on the stock.

Several other equities analysts also recently issued reports on FMS. Berenberg Bank assumed coverage on shares of Fresenius Medical Care in a report on Wednesday, November 6th. They set a "buy" rating and a $25.60 price objective on the stock. Bank of America upgraded shares of Fresenius Medical Care from an "underperform" rating to a "neutral" rating in a research note on Monday, December 2nd. Finally, Truist Financial lifted their price objective on shares of Fresenius Medical Care from $22.00 to $23.00 and gave the stock a "hold" rating in a research note on Monday, October 7th. One research analyst has rated the stock with a sell rating, two have given a hold rating, one has given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $24.30.

Fresenius Medical Care Stock Up 1.0 %

Shares of FMS stock traded up $0.23 during trading hours on Friday, reaching $22.38. 186,867 shares of the company's stock were exchanged, compared to its average volume of 210,333. The company has a current ratio of 1.37, a quick ratio of 1.02 and a debt-to-equity ratio of 0.42. The company has a market cap of $13.13 billion, a price-to-earnings ratio of 18.50, a P/E/G ratio of 0.96 and a beta of 0.93. Fresenius Medical Care has a fifty-two week low of $17.93 and a fifty-two week high of $24.31. The stock's 50 day moving average is $22.21 and its 200-day moving average is $20.64.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in FMS. Allworth Financial LP lifted its position in shares of Fresenius Medical Care by 53.1% in the third quarter. Allworth Financial LP now owns 1,675 shares of the company's stock valued at $36,000 after acquiring an additional 581 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new position in Fresenius Medical Care in the 3rd quarter valued at $38,000. GAMMA Investing LLC boosted its stake in Fresenius Medical Care by 50.4% during the 3rd quarter. GAMMA Investing LLC now owns 4,998 shares of the company's stock worth $106,000 after purchasing an additional 1,675 shares during the last quarter. ORG Wealth Partners LLC purchased a new stake in shares of Fresenius Medical Care during the third quarter worth $112,000. Finally, Venturi Wealth Management LLC raised its position in shares of Fresenius Medical Care by 1,045.8% in the third quarter. Venturi Wealth Management LLC now owns 5,259 shares of the company's stock valued at $112,000 after buying an additional 4,800 shares during the last quarter. Hedge funds and other institutional investors own 8.37% of the company's stock.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.